Liberal Democratic Party (LDP) leader Fumio Kishida was sworn in as Japan’s 100th prime minister. While a major focus is on how he will embody his centerpiece policy proposals made during the LDP campaign, another key topic is how the…
REGULATORY
MHLW Panel Recommends Lifting Ban on Cannabis-Derived Drugs, Eyes Legal Amendment Next Spring
A health ministry study group on cannabis control measures compiled a proposal on June 11 calling for the lifting of the ban on cannabis-derived drugs and the promotion of the proper use of medical narcotics. Based on the recommendations, the…
To read the full story
Related Article
REGULATORY
- Chuikyo Discusses Spillover Rules in Market Expansion Re-Pricing, PMP Criteria towards FY2022 Reform
October 21, 2021
- MHLW Health Service Chief Wants Prompt Debate on HPV Recommendation
October 20, 2021
- Average Price Gap for FY2022 Revision Likely to Be 8% Level or Lower: Wholesalers
October 20, 2021
- Japan to Boost Budgets for Vaccine Development and Supply: Govt Official
October 19, 2021
- Govt to Deliver 4.12 Million Comirnaty Doses for COVID-19 Boosters: Minister
October 19, 2021
If you were able to make more money at a company you found less desirable than your current one, would it be worth it? Conversely, would you move to a better company and a better role and accept less pay?…
The average ratio of female employees at managerial posts stood at just 12.5% at pharmaceutical companies operating in Japan, a Jiho survey revealed. While foreign drug makers had an average 25.0%, the ratio came to as low as 9.8% for…
Biogen’s controversial Alzheimer’s drug aducanumab was filed for Japanese regulatory approval in December. If approved, it will be the first…
Japan’s key reimbursement policy panel on December 20 approved an outline of its FY2020 drug pricing reform next April, with…
Japan will go ahead with the introduction of a cost-effectiveness assessment (CEA) scheme for drugs and medical devices in April…